• Molecular NameSulfinpyrazone
  • SynonymDiphenylpyrazone; Sulfinpyrazine; Sulfinpyrazon; Sulfoxyphenylpyrazolidine; Sulphinpyrazone; Usaf Ge-13
  • Weight404.49
  • Drugbank_IDDB01138
  • ACS_NO57-96-5
  • Show 2D model
  • LogP (experiment)3.015
  • LogP (predicted, AB/LogP v2.0)2.0
  • pka2.8 (22°)
  • LogD (pH=7, predicted)-1.75
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-1.98
  • LogSw (predicted, AB/LogsW2.0)0.73
  • Sw (mg/ml) (predicted, ACD/Labs)0.11
  • No.of HBond Donors0
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds6
  • TPSA76.9
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA uricosuric medication used to treat gout. It also sometimes is used to reduce platelet aggregation by inhibiting degranulation of platelets which reduces the release of ADP and thromboxane.
  • Absorption_value100.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability100.0
  • Protein binding98.3
  • Volume of distribution (VD)0.06 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmAround 50% of an orally administered dose appears in urine after 24 h, 90% as unchanged drug and 10% as its active metabolite, N 1 -p-hydroxyphenol.
  • Half life3~5 h, sulfide metabolite about 14 to 21 h.
  • Excretionrenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include nausea, vomiting, diarrhea, epigastric pain, ataxia, labored respiration, convulsions, coma. Possible symptoms, seen after overdosage with other pyrazolone derivatives: anemia, jaundice, and ulceration.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A